Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

Hôpital Erasme, Brussels

Cliniques Universitaires Saint-Luc, Brussels

Antwerp University Hospital, Edegem

Seoul National University Hospital, Seoul

Universitätsspital Basel, Basel

Samsung Medical Center, Seoul

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

Humanitas Cancer Center, Istituto Clinico Humanitas IRCCS, Rozzano

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

Universitätsklinikum Hamburg-Eppendorf (UKE), Hamburg

Ospedale San Gerardo, Monza

Hospital General Universitario Gregorio Marañón, Madrid

Hospital Universitario 12 de Octubre, Madrid

Winship Cancer Institute of Emory University, Atlanta

Medizinische Hochschule Hannover (MHH), Hanover

Mayo Clinic, Jacksonville

Istituto Oncologico Veneto - IRCCS, Padua

Vanderbilt-Ingram Cancer Center, Nashville

CHU Grenoble Alpes, La Tronche

Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna

Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz

Mayo Clinic, Rochester

Azienda Ospedaliero-Universitaria Pisana, Pisa

Universitätsklinikum Frankfurt, Frankfurt am Main

Universitätsklinikum des Saarlandes, Homburg

The University of Texas Southwestern Medical Center, Dallas

University of Texas MD Anderson Cancer Center, Houston

Mayo Clinic, Phoenix

Gustave Roussy, Villejuif

University of Washington Medical Center, Seattle

Moffitt Cancer Center, Tampa

Memorial Sloan Kettering Cancer Center - Sidney Kimmel Center for Prostate and Urologic Cancers, New York

Tom Baker Cancer Centre, Calgary

Princess Margaret Cancer Centre, Toronto

St. James's Hospital, Dublin

Vall d'Hebrón University Hospital, Barcelona

Catalan Institute of Oncology, Barcelona

University College London Hospitals NHS Foundation Trust, Euston

Beatson West of Scotland Cancer Centre, Glasgow

The Royal Marsden, Sutton